Cerus Corporation 2022 Form 10-K Summary
Business context and reporting period
Cerus develops and commercializes the INTERCEPT Blood System, designed to reduce pathogens in donated blood components. Commercial products include systems for platelets, plasma and cryoprecipitation; the red blood cell system remains in development. This filing covers the fiscal year ended December 31, 2022, rather than a standalone fourth quarter.
Platelet and plasma products were marketed in the United States and selected international markets. INTERCEPT Fibrinogen Complex had limited U.S. commercialization. Cerus had 309 employees at year-end and operated as one blood-safety segment.
Financial performance and liquidity
| Metric | 2022 | 2021 | Change |
|---|---|---|---|
| Product revenue | $162.0 million | $130.9 million | 24% |
| Government contract revenue | $26.3 million | $28.7 million | (8%) |
| Total revenue | $188.3 million | $159.5 million | 18% |
| Gross profit on product revenue | $87.1 million | $67.4 million | 29% |
| Product gross margin | 54% | 51% | +3 percentage points |
| Loss from operations | $(34.1) million | $(48.9) million | Improved |
| Net loss attributable to Cerus | $(42.8) million | $(54.4) million | Improved |
| Basic and diluted loss per share | $(0.24) | $(0.32) | Improved |
| Cash used in operations | $(25.6) million | $(33.9) million | Improved |
Product revenue growth was driven primarily by higher U.S. platelet-kit volumes, partly associated with the FDA platelet safety guidance effective October 1, 2021. North American product revenue increased to $104.0 million from $69.0 million, while Europe, the Middle East and Africa declined to $56.3 million from $60.1 million, partly due to a weaker euro.
Research and development expense was $64.1 million, essentially flat year over year. Selling, general and administrative expense increased 3% to $83.3 million. Net non-operating expense increased to $8.3 million from $5.1 million, reflecting higher interest expense, foreign exchange losses and a $2.2 million impairment of certain preferred-stock and warrant investments. Product gross margin improved, but the company remained unprofitable; calculated net margin was approximately negative 23% of total revenue.
| Liquidity and capital structure | December 31, 2022 | December 31, 2021 |
|---|---|---|
| Cash and cash equivalents | $35.6 million | $48.8 million |
| Short-term investments | $66.6 million | $80.6 million |
| Restricted cash | $1.8 million | $2.3 million |
| Total cash, investments and restricted cash | $103.9 million | $131.6 million |
| Total debt | $69.8 million | $69.4 million |
| Working capital | $53.1 million | $108.5 million |
Debt included $55.0 million of term-loan principal and $14.9 million drawn on a revolving facility. The term loan had an effective interest rate of approximately 9.9% at year-end, with $41.25 million of principal classified as current and scheduled for repayment in 2023. The company stated that its cash, investments, product receipts and government reimbursements were expected to fund requirements for at least the next 12 months, but noted that this assessment depends on assumptions that may prove incorrect.
Material changes versus the prior comparable period
- Total revenue increased 18%, led by 24% growth in product revenue; government contract revenue declined because 2021 included a one-time BARDA revenue true-up.
- Operating loss narrowed by $14.9 million, and net loss narrowed by $11.6 million.
- Operating cash burn improved by $8.3 million, but total liquidity declined by $27.7 million as the company funded operations, inventory, product development and commercialization.
- Working capital decreased by $55.5 million, primarily because of higher current debt, continued operating cash use, inventory investments and commercialization spending.
- Interest expense increased 18% to $5.8 million, and other expense included impairment of certain investments.
- Product revenue became more concentrated: the American Red Cross represented 35% of product revenue and Établissement Français du Sang represented 12%.
- Cerus entered a 2022 supply and manufacturing agreement with Fresenius extending through December 31, 2031, subject to renewal and termination provisions.
- BARDA committed an additional $23 million in 2022, bringing committed funding to up to $148.9 million; potential total funding could reach $245.9 million through 2025 if additional options are exercised.
- The company received a Department of Justice Antitrust Division civil investigative demand in November 2022 concerning contracting and information-exchange practices. No claim or proceeding had been initiated as of the filing date.
- The filing disclosed an immaterial correction to the classification of foreign-currency effects in the 2020 cash-flow statement.
Guidance, outlook, management commentary and risks
Management did not provide a formal numerical revenue or earnings forecast. It expects future product revenue to benefit from broader adoption of INTERCEPT, increased platelet-kit volumes and growth in IFC, but expects first-half 2023 comparisons to face headwinds from seasonality, foreign exchange and customer inventory management.
Cerus expects continued operating losses until widespread commercial adoption is achieved, which may never occur. Planned spending includes U.S. commercialization of platelet, plasma and IFC products; red blood cell clinical and regulatory development; post-approval platelet studies; new product configurations; illuminator redesign; manufacturing-capacity expansion; and compliance and legal costs.
- The red blood cell system has not been commercialized. Its European MDR certification remains uncertain, and U.S. RedeS and ReCePI Phase 3 studies experienced COVID-19-related enrollment delays. Antibody events and further clinical holds remain possible.
- BARDA funding is milestone- and option-dependent and may be reduced, delayed or terminated for convenience. The company may need additional capital to complete development programs.
- The term loan requires substantial principal payments beginning in 2023, creating refinancing and liquidity risk.
- Cerus relies heavily on Fresenius and other sole or limited-source suppliers. Risks include capacity constraints, component obsolescence, manufacturing nonconformities and regulatory approval of alternate sites or components.
- The current illuminator is being phased out because of obsolete components; the redesigned illuminator requires regulatory approval and may not be available on schedule.
- Platelet and plasma CE certifications under the older MDD framework expire in 2024, and MDR certification remains under review.
- Market adoption depends on a concentrated customer base, reimbursement, blood-center and hospital implementation, compatible collection methods and competition from pathogen-reduction, testing and conventional products.
- COVID-19 effects, inflation, interest rates, foreign-exchange movements, supply-chain disruptions, geopolitical conditions and staffing shortages may increase costs or delay commercialization and clinical programs.
Most important facts for investors to verify
- Whether product revenue growth and U.S. platelet-kit adoption continue after customer inventory adjustments and the 2023 comparison headwinds.
- The timing and terms of refinancing or repayment of the $55.0 million term loan, including the $41.25 million current portion.
- Actual cash burn and whether available liquidity remains sufficient without additional equity, debt or government funding.
- BARDA option exercises, milestone performance and the availability of the remaining potential funding.
- Progress and regulatory outcomes for the red blood cell system, including the status of clinical trials, antibody events and European MDR review.
- Renewal or replacement of key supplier arrangements and availability of the redesigned illuminator and other obsolete components.
- Expansion of IFC commercialization, including blood-center licenses, hospital adoption and product economics.
- The scope, duration and outcome of the Department of Justice Antitrust Division investigation and related legal costs.
- Customer concentration, particularly the American Red Cross and Établissement Français du Sang, and the durability of their purchase levels.